At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 4,548 enrolled
Drug / intervention
Telcagepant +1 moredrug
Likely dose
Telcagepant 140 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Six Month Phase II/III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Telcagepant (MK-0974) for Prevention of Menstrually Related Migraine in Female Patients With Episodic Migraine
In Brief
A Phase 3 clinical trial evaluating Telcagepant and Placebo for Migraine. Completed, enrolled 4,548 participants.
Detailed Summary
This is a multicenter study to test the hypothesis that telcagepant is superior to placebo in preventing perimenstrual migraines as measured by mean monthly headaches during the entire treatment period. This study will also evaluate the safety and tolerability of telcagepant for female migraine participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2010
Enrollment StartJun 2010
Primary CompletionApr 2011
TodayJul 2026
First PostedMay 18, 2010
Enrollment StartJun 1, 2010
Primary CompletionApr 8, 2011
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 16.1 years ago
Interventions
Telcagepantdrug
Telcagepant 140 mg film coated tablet for oral administration
Placebodrug
Placebo to match telcagepant 140 mg film coated tablet for oral administration